A Multi-Center, Open-Label Study
NCT01468259
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Renal Disease
End Stage Renal Disease
Interventions
DRUG:
Droxidopa
Sponsor
Chelsea Therapeutics